bluebird bio, Inc. (BLUE): Price and Financial Metrics

bluebird bio, Inc. (BLUE)

Today's Latest Price: $60.81 USD

0.86 (-1.39%)

Updated May 28 6:55pm

Add BLUE to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

BLUE Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for BLUE is 0.05 -- better than only 10.77% of US stocks.
  • BLUE's price/sales ratio is 62.59; that's higher than the P/S ratio of 96.84% of US stocks.
  • BLUE's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 16.09% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to bluebird bio Inc are ARVN, RESN, APTX, FPRX, and RGNX.
  • BLUE's SEC filings can be seen here. And to visit bluebird bio Inc's official web site, go to
BLUE Daily Price Range
BLUE 52-Week Price Range

BLUE Stock Price Chart More Charts

BLUE Price/Volume Stats

Current price $60.81 52-week high $143.98
Prev. close $61.67 52-week low $38.95
Day low $60.47 Volume 1,105,000
Day high $63.85 Avg. volume 1,255,715
50-day MA $53.00 Dividend yield N/A
200-day MA $79.10 Market Cap 3.38B

bluebird bio, Inc. (BLUE) Company Bio

Bluebird Bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies. The company was founded in 1992 and is based in Cambridge, Massachusetts.

BLUE Latest News Stream

Event/TimeNews Detail
Loading, please wait...

BLUE Latest Social Stream

Loading social stream, please wait...

View Full BLUE Social Stream

Latest BLUE News From Around the Web

Below are the latest news stories about bluebird bio Inc that investors may wish to consider to help them evaluate BLUE as an investment opportunity.

What Sanofi Might Buy With Its Regeneron Windfall

The drug company has not said what it plans to do with the cash, but analysts speculate that it will pursue a gene therapy company worth around $5 billion.

Yahoo | May 27, 2020

Bluebird (BLUE) Upgraded to Buy: What Does It Mean for the Stock?

Bluebird (BLUE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

Yahoo | May 25, 2020

FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?”

Between a string of avoidable problems and instability in the market, bluebird bio might be in for a rough decade.

Yahoo | May 22, 2020

Bluebird Prices New Shares At $55, Seeks To Raise $500 Million

Bluebird Bio (BLUE) priced an offering of 9.09 million shares of its common stock at $55 each, the company said late on Monday. The post Bluebird Prices New Shares At $55, Seeks To Raise $500 Million appeared first on Smarter Analyst .

Smarter Analyst | May 19, 2020

Bluebird Bio's stock falls after proposed public stock offering

Shares of Bluebird Bio Inc. undefined fell 2.9% in premarket trading Monday, after the gene therapy company said it was proposing a public offering of $400…

MarketWatch | May 18, 2020

Read More 'BLUE' Stories Here

BLUE Price Returns

1-mo 7.61%
3-mo -15.93%
6-mo -24.87%
1-year -49.55%
3-year -22.09%
5-year -68.69%
YTD -30.70%
2019 -11.54%
2018 -44.30%
2017 188.65%
2016 -3.92%
2015 -29.98%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1498 seconds.